No black box warning on record for Aptivus

As of the latest FDA labeling reviewed, Aptivus (TIPRANAVIR) does not carry a black box warning. Standard warnings and precautions still apply — see the full Aptivus medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Co-administration with Ritonavir: APTIVUS must be co-administered with ritonavir and food to achieve the desired antiviral effect. Failure to administer APTIVUS with ritonavir and food may result in a loss of efficacy of tipranavir. ( 5.1 ) Hepatic Impairment: Discontinue for signs and symptoms of clinical hepatitis or asymptomatic increases in ALT/AST >10 times ULN or a

No black box warning on record for Aptivus

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Co-administration with Ritonavir: APTIVUS must be co-administered with ritonavir and food to achieve the desired antiviral effect. Failure to administer APTIVUS with ritonavir and food may result in a loss of efficacy of tipranavir. ( 5.1 ) Hepatic Impairment: Discontinue for signs and symptoms of clinical hepatitis or asymptomatic increases in ALT/AST >10 times ULN or a

Aptivus Black Box Warning

No black box warning on record for Aptivus

Other warnings & precautions

Aptivus Black Box Warning

No black box warning on record for Aptivus

Other warnings & precautions